Literature DB >> 26211626

The FHL2 regulation in the transcriptional circuitry of human cancers.

Cyanne Ye Cao1, Simon Wing-Fai Mok2, Vincent Wing-Sang Cheng1, Stephen Kwok-Wing Tsui1.   

Abstract

The Four-and-a-half LIM (FHL)-only protein is a subfamily of protein members under the LIM-only protein family. These proteins are identified by their characteristic four and a half cysteinerich LIM homeodomain. Five members have been categorized into the FHL subfamily, which are FHL1, FHL2, FHL3, FHL4 and activator of CREM in testis (ACT) in human. FHL2 is amongst the most examined members within the family. Fhl2, the gene that code for the protein, is transcriptionally regulated by diverse types of transcription factors, for example, p53, serum response factor (SRF), and specificity protein 1 (Sp1). The expression of FHL2 is found in different tissues and organs and has been reported as a critical participant influencing the wide types of cancer such as breast cancer, gastrointestinal (GI) cancers, liver cancer and prostate cancer. The expression profile of FHL2 appeared to have a significant functional role in the carcinogenesis of these cancers which are mediated by different types of transcription factor including both tumor suppressors and inducers. In this review, we will first describe the molecular network governing FHL2 expression, which focus on the transcription factors conveying FHL2-initiated responses. In the second part, FHL2-linked cancers and the underlying molecular machinery will be discussed. Factors other than transcriptional regulation which may involve the cancer progression such as mutations of fhl2 and posttranslational modifications of the protein will also be mentioned.
Copyright © 2015. Published by Elsevier B.V.

Entities:  

Keywords:  Bioinformatics; Breast cancer; Four-and-a-half Lim (FHL2); Gastrointestinal cancer (GI cancer); Hepatocellular carcinoma (HCC); Liver cancer; Nucleus translocation; Prostate cancer; Serum response factor (SRF); Specificity protein 1 (SP1); Transcriptional regulation; p53

Mesh:

Substances:

Year:  2015        PMID: 26211626      PMCID: PMC5975090          DOI: 10.1016/j.gene.2015.07.043

Source DB:  PubMed          Journal:  Gene        ISSN: 0378-1119            Impact factor:   3.688


  67 in total

1.  The LIM-only proteins FHL2 and FHL3 interact with alpha- and beta-subunits of the muscle alpha7beta1 integrin receptor.

Authors:  Thomas Samson; Neil Smyth; Stefanie Janetzky; Olaf Wendler; Judith M Müller; Roland Schüle; Helga von der Mark; Klaus von der Mark; Viktor Wixler
Journal:  J Biol Chem       Date:  2004-04-26       Impact factor: 5.157

Review 2.  The LIM domain: from the cytoskeleton to the nucleus.

Authors:  Julie L Kadrmas; Mary C Beckerle
Journal:  Nat Rev Mol Cell Biol       Date:  2004-11       Impact factor: 94.444

3.  Androgen receptor coactivators lysine-specific histone demethylase 1 and four and a half LIM domain protein 2 predict risk of prostate cancer recurrence.

Authors:  Philip Kahl; Lucia Gullotti; Lukas Carl Heukamp; Susanne Wolf; Nicolaus Friedrichs; Roland Vorreuther; Gerold Solleder; Patrick J Bastian; Jörg Ellinger; Eric Metzger; Roland Schüle; Reinhard Buettner
Journal:  Cancer Res       Date:  2006-12-01       Impact factor: 12.701

4.  A family of LIM-only transcriptional coactivators: tissue-specific expression and selective activation of CREB and CREM.

Authors:  G M Fimia; D De Cesare; P Sassone-Corsi
Journal:  Mol Cell Biol       Date:  2000-11       Impact factor: 4.272

5.  Mechanisms of disease: epithelial-mesenchymal transition--does cellular plasticity fuel neoplastic progression?

Authors:  Eva A Turley; Mandana Veiseh; Derek C Radisky; Mina J Bissell
Journal:  Nat Clin Pract Oncol       Date:  2008-03-18

6.  Hepatic tumor-stroma crosstalk guides epithelial to mesenchymal transition at the tumor edge.

Authors:  F van Zijl; M Mair; A Csiszar; D Schneller; G Zulehner; H Huber; R Eferl; H Beug; H Dolznig; W Mikulits
Journal:  Oncogene       Date:  2009-08-31       Impact factor: 9.867

7.  Structural analysis of four and half LIM protein-2 in dilated cardiomyopathy.

Authors:  Takuro Arimura; Takeharu Hayashi; Yuji Matsumoto; Hiroki Shibata; Shitoshi Hiroi; Takeyuki Nakamura; Natsuko Inagaki; Kunihiko Hinohara; Megumi Takahashi; Satoh-Itoh Manatsu; Taishi Sasaoka; Toru Izumi; Gisèle Bonne; Ketty Schwartz; Akinori Kimura
Journal:  Biochem Biophys Res Commun       Date:  2007-03-30       Impact factor: 3.575

8.  SKI activates Wnt/beta-catenin signaling in human melanoma.

Authors:  Dahu Chen; Weidong Xu; Elise Bales; Clemencia Colmenares; Maralice Conacci-Sorrell; Shunsuke Ishii; Ed Stavnezer; Judith Campisi; David E Fisher; Avri Ben-Ze'ev; Estela E Medrano
Journal:  Cancer Res       Date:  2003-10-15       Impact factor: 12.701

9.  DRAL is a p53-responsive gene whose four and a half LIM domain protein product induces apoptosis.

Authors:  F A Scholl; P McLoughlin; E Ehler; C de Giovanni; B W Schäfer
Journal:  J Cell Biol       Date:  2000-10-30       Impact factor: 10.539

10.  The LIM-only protein FHL2 interacts with beta-catenin and promotes differentiation of mouse myoblasts.

Authors:  Bernd Martin; Richard Schneider; Stefanie Janetzky; Zoe Waibler; Petra Pandur; Michael Kühl; Jürgen Behrens; Klaus von der Mark; Anna Starzinski-Powitz; Viktor Wixler
Journal:  J Cell Biol       Date:  2002-10-07       Impact factor: 10.539

View more
  15 in total

1.  Four and a half LIM domains 2 contributes to the development of human tongue squamous cell carcinoma.

Authors:  Qiang Wang; Xiaoying Wang; Xiufen Tian; Ronghua Tang; Xin Xu
Journal:  J Mol Histol       Date:  2016-01-12       Impact factor: 2.611

2.  Deletion of FHL2 in fibroblasts attenuates fibroblasts activation and kidney fibrosis via restraining TGF-β1-induced Wnt/β-catenin signaling.

Authors:  Ying Duan; Yumei Qiu; Xiaowen Huang; Chunsun Dai; Junwei Yang; Weichun He
Journal:  J Mol Med (Berl)       Date:  2020-01-11       Impact factor: 4.599

3.  Matrix mechanics controls FHL2 movement to the nucleus to activate p21 expression.

Authors:  Naotaka Nakazawa; Aneesh R Sathe; G V Shivashankar; Michael P Sheetz
Journal:  Proc Natl Acad Sci U S A       Date:  2016-10-14       Impact factor: 11.205

4.  Mechanosensing through Direct Binding of Tensed F-Actin by LIM Domains.

Authors:  Xiaoyu Sun; Donovan Y Z Phua; Lucas Axiotakis; Mark A Smith; Elizabeth Blankman; Rui Gong; Robert C Cail; Santiago Espinosa de Los Reyes; Mary C Beckerle; Clare M Waterman; Gregory M Alushin
Journal:  Dev Cell       Date:  2020-10-14       Impact factor: 12.270

5.  Krüppel-like factor 8 induces epithelial-to-mesenchymal transition and promotes invasion of pancreatic cancer cells through transcriptional activation of four and a half LIM-only protein 2.

Authors:  Xiaoping Yi; Hongyan Zai; Xueying Long; Xiaoyi Wang; Wenzheng Li; Yixiong Li
Journal:  Oncol Lett       Date:  2017-08-09       Impact factor: 2.967

6.  Oxymatrine Synergistically Enhances Doxorubicin Anticancer Effects in Colorectal Cancer.

Authors:  Di Pan; Wen Zhang; Nenling Zhang; Yini Xu; Yi Chen; Jianqing Peng; Yan Chen; Yanyan Zhang; Xiangchun Shen
Journal:  Front Pharmacol       Date:  2021-06-30       Impact factor: 5.810

Review 7.  Multi-phenotypic Role of Serum Response Factor in the Gastrointestinal System.

Authors:  Seungil Ro
Journal:  J Neurogastroenterol Motil       Date:  2016-04-30       Impact factor: 4.924

8.  Transcriptome of the GSH-Depleted Lens Reveals Changes in Detoxification and EMT Signaling Genes, Transport Systems, and Lipid Homeostasis.

Authors:  Jeremy A Whitson; Xiang Zhang; Mario Medvedovic; Jenny Chen; Zongbo Wei; Vincent M Monnier; Xingjun Fan
Journal:  Invest Ophthalmol Vis Sci       Date:  2017-05-01       Impact factor: 4.799

Review 9.  PPARs and Mitochondrial Metabolism: From NAFLD to HCC.

Authors:  Tommaso Mello; Maria Materozzi; Andrea Galli
Journal:  PPAR Res       Date:  2016-12-27       Impact factor: 4.964

10.  BAG3 Overexpression and Cytoprotective Autophagy Mediate Apoptosis Resistance in Chemoresistant Breast Cancer Cells.

Authors:  Chandan Kanta Das; Benedikt Linder; Florian Bonn; Florian Rothweiler; Ivan Dikic; Martin Michaelis; Jindrich Cinatl; Mahitosh Mandal; Donat Kögel
Journal:  Neoplasia       Date:  2018-02-22       Impact factor: 5.715

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.